Patents by Inventor John O. Link

John O. Link has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12084467
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: September 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Julie Farand, Tezcan Guney, Darryl Kato, John O. Link, James B. C. Mack, Dong Min Mun, William J. Watkins, Jennifer R. Zhang
  • Patent number: 12084455
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: September 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • Patent number: 12077537
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: September 3, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Publication number: 20240254137
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Application
    Filed: December 11, 2023
    Publication date: August 1, 2024
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Patent number: 12037340
    Abstract: Provided herein are compounds of Formula (I): the formula(I): wherein the various substituents are defined herein.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: July 16, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elbert Chin, John O. Link, James G. Taylor, Zheng-Yu Yang
  • Patent number: 11993583
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: May 28, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, John O. Link, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • Publication number: 20240132527
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Application
    Filed: August 22, 2023
    Publication date: April 25, 2024
    Inventors: Julie Farand, Michael Graupe, Tezcan Guney, Darryl Kato, Jiayao Li, John O. Link, James B. C. Mack, Dong Min Mun, Roland D. Saito, William J. Watkins, Jennifer R. Zhang
  • Patent number: 11905299
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Patent number: 11787825
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: October 17, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Julie Farand, Tezcan Guney, Darryl Kato, John O. Link, James B. C. Mack, William J. Watkins
  • Publication number: 20230312567
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Application
    Filed: February 15, 2023
    Publication date: October 5, 2023
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Publication number: 20230212148
    Abstract: Background: HIV capsid (CA) is an emerging target for antiretroviral treatment PF-3450074 (P74) is a small-molecule CA binder that has been proposed to inhibit reverse transcription (RT) by accelerating HIV core uncoating. PF74 antiviral potency can depend on cyclophilin A (CypA) binding to CA in some cells and it shares a CA binding site with the host nuclear transport factor CPSF6, which restrict HIV infection when mislocalized to the cell cytoplasm. Here we further interrogate the mechanism of action (MOA) for PF74 in human T cells and clarify its potential dependence on CypA and CPSF6. Methodology: HIV reporter viruses were produced in HEK293T cells and used to infect MT2 cells and primary CD4+ T cells to determine the antiviral effect of PF74. Compound exposure was controlled by staggered addition and cell washing at various times post-infection. DNA products of infection were analyzed by qPCR. CypA and CPSF6 levels were varied in MT2 cells by overexpression and shRNA knockdown.
    Type: Application
    Filed: December 2, 2022
    Publication date: July 6, 2023
    Inventors: Gediminas J. Brizgys, Chienhung Chou, Hang Chu, Julie Farand, Michael Graupe, Tezcan Guney, Darryl Kato, Jiayao Li, John O. Link, James B.C. Mack, Dong Min Mun, Scott D. Schroeder, William J. Watkins, Qiaoyin Wu, Jennifer R. Zhang
  • Publication number: 20230203071
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Application
    Filed: December 2, 2022
    Publication date: June 29, 2023
    Inventors: Zhimin Du, Julie Farand, Tezcan Guney, Darryl Kato, John O. Link, James B.C. Mack, Dong Min Mun, William J. Watkins, Jennifer R. Zhang
  • Publication number: 20230203069
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Application
    Filed: December 2, 2022
    Publication date: June 29, 2023
    Inventors: Julie Farand, Michael Graupe, Tezcan Guney, Darryl Kato, Jiayao Li, John O. Link, James B. C. Mack, Dong Min Mun, Roland D. Saito, William J. Watkins, Jennifer R. Zhang
  • Patent number: 11680064
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 20, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Publication number: 20230027055
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Application
    Filed: April 7, 2021
    Publication date: January 26, 2023
    Inventors: Elizabeth M. Bacon, Elbert Chin, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, John O. Link, Nathan Shapiro, Teresa Alejandra Trejo Martin, Zheng-Yu Yang
  • Publication number: 20230012449
    Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: April 27, 2021
    Publication date: January 12, 2023
    Inventors: Steven S. Bondy, Carina E. Cannizzaro, Chien-Hung Chou, Randall L. Halcomb, Yunfeng E. Hu, John O. Link, Qi Liu, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Publication number: 20230002407
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Application
    Filed: May 11, 2021
    Publication date: January 5, 2023
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Publication number: 20220411434
    Abstract: Provided herein are compounds of Formula (I): the formula(I): wherein the various substituents are defined herein,
    Type: Application
    Filed: May 19, 2022
    Publication date: December 29, 2022
    Inventors: Elbert Chin, John O. Link, James G. Taylor, Zheng-Yu Yang
  • Publication number: 20220402931
    Abstract: Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula(I): Wherein the variable substituents are described herein.
    Type: Application
    Filed: May 19, 2022
    Publication date: December 22, 2022
    Inventors: Elbert Chin, John O. Link, Ezra Roberts, James G. Taylor, Zheng-Yu Yang
  • Patent number: 11318119
    Abstract: The present disclosure provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject. The disclosure also provides pharmaceutical compositions comprising these compounds, processes for preparing them, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject using these compounds. The present disclosure also provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of a coronavirus, treating coronavirus symptoms or delaying the onset of coronavirus symptoms in a subject.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: May 3, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Aesop Cho, John O. Link, Jie Xu